$4.99
0.449.67%
Last update: Nov 4, 2:46 PM
Prime Medicine Inc (PRME) Stock Price, Quote, News & History
PRMENASDAQ
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
You can purchase shares of Prime Medicine (NASDAQ:PRME) through any online brokerage.
Other companies in Prime Medicine’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Prime Medicine has a consensus price target of $9.60.
The stock price for Prime Medicine (NASDAQ: PRME) is $4.99 last updated November 4, 2026 at 2:46 PM EST.
There are no upcoming dividends for Prime Medicine.
Prime Medicine does not have any upcoming earnings scheduled.
There is no upcoming split for Prime Medicine.
Prime Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired...
